Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Autophagy and inflammasome activation are associated with poor response to FLT3 inhibitors in patients with FLT3-ITD acute myeloid leukemia.

Scientific reports - 12 Oct 2024

Santos de Macedo Brunno Gilberto, Albuquerque de Melo Manuela, Pereira-Martins Diego Antonio, Machado-Neto João Agostinho, Traina Fabíola

Abstract excerpt

Beyond its clinical diversity and severity, acute myeloid leukemia (AML) is known for its complex molecular background and for rewiring biological processes to aid disease onset and maintenance. FLT3 mutations are among the most recurring molecular entities that cooperatively drive AML, and their inhibition is a critical molecularly oriented therapeutic strategy. Despite being a promising avenue, it still faces...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy
Share to Benzothiazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to fms-Like Tyrosine Kinase 3

Share to Inflammasomes

Share to Leukemia, Myeloid, Acute

Share to Phenylurea Compounds

Share to Sorafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 39396074
DOI: 10.1038/s41598-024-74168-z
PMCID: PMC11470923

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Autophagy and inflammasome activation are associated with poor response to FLT3 inhibitors in patients with FLT3-ITD acute myeloid leukemia.PMID 39396074Read ↗

Autophagy and inflammasome molecular interplay and activation predict poor response to FLT3 inhibitors in patients with FLT3-ITD acute myeloid leukemiaSemantic proximity Read ↗

Multi-omics integration reveals immune hallmarks and biomarkers associated with FLT3 inhibitor sensitivity in FLT3-mutated AMLSemantic proximity Read ↗

Targeting NLRP3 inhibits AML progression by inducing PERK/eIF2-mediated apoptosisSemantic proximity Read ↗

Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation.Semantic proximity Read ↗

Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia.Semantic proximity Read ↗

Quizartinib and omacetaxine mepesuccinate combination therapy in FLT3-ITD AML: a phase II trial.Semantic proximity Read ↗

The NLRP3 Inflammasome and Its Role in the Pathogenicity of LeukemiaSemantic proximity Read ↗

Evolving paradigms in targeting FLT3 for acute myeloid leukemia therapy.Semantic proximity Read ↗

Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemiaSemantic proximity Read ↗

Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells.Semantic proximity Read ↗

Potential role of autophagy induced by FLT3-ITD and acid ceramidase in acute myeloid leukemia chemo-resistance: new insights.Semantic proximity Read ↗

The NLRP3/eIF2 axis drives cell cycle progression in acute myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.